HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for BriaCell Therapeutics, maintaining a price target of $15.
October 03, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for BriaCell Therapeutics, maintaining a price target of $15.
The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. is a positive signal for BriaCell Therapeutics. This suggests confidence in the company's future performance and could lead to increased investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100